The treatment of HER2-positive metastatic breast cancer (mBC) has advanced significantly in recent decades. Trastuzumab, introduced in 1998, improved survival when added to chemotherapy. Since then, other HER2-targeted agents like pertuzumab, T-DM1, and lapatinib have been approved, further extending progression-free and overall survival. These treatments have given most patients 2-4 years of disease control, but resistance still eventually develops. New strategies aim to prevent or overcome resistance by employing antibody-drug conjugates and combinations to hit multiple targets. The goal is to utilize all effective options in a sequential or combinatorial way until loss of benefit, thereby extending survival as long as possible.
羅氏大藥廠股份有限公司
羅氏大藥廠專注於重大未滿足醫療需求及具專業之領域，包含癌症、免疫、感染性疾病、眼科及中樞神經系統五大領域。自創立以來，已陸續推出多種深受醫藥界和患者推崇的優良產品，例如：神經安定劑、抗巴金森氏症藥物、抗生素、干擾素、紅血球生成素、抗病毒藥物、器官移植抗排斥劑、抗癌製劑、流行性感冒藥物、B型及C 型肝炎製劑、類風濕性關節炎製劑及免疫療法。